What is Brainsgate?
Established in 2000, BrainsGate is at the forefront of developing novel therapies for patients suffering from Central Nervous System (CNS) diseases. The company's proprietary platform technology centers on the electrical stimulation of the Spheno-Palatine Ganglion (SPG) to enhance cerebral blood flow. This innovative approach is particularly aimed at addressing critical health issues such as ischemic stroke, a leading cause of long-term disability. BrainsGate's advanced medical solutions offer new hope for patients with a range of CNS conditions, positioning the company as a key player in the neuro-medical device sector.
How much funding has Brainsgate raised?
Brainsgate has raised a total of $40M across 2 funding rounds:
Unspecified
$26M
Private Equity
$14M
Unspecified (2015): $26M with participation from Elron Electronic Industries
Private Equity (2020): $14M led by Pitango Venture Capital, Agate Inc, Medtronic plc, Elron Electronic Industries Ltd., Cipio, BNP Paribas, and Spero Health Inc
Key Investors in Brainsgate
Elron Electronic Industries
Elron Electronic Industries is a foundational Israeli technology holding company with a broad investment focus, including medical technology, and has a history of supporting innovative ventures.
Pitango Venture Capital
Pitango Venture Capital is a leading venture capital firm that supports visionary entrepreneurs and groundbreaking companies, with a dedicated HealthTech fund, indicating a focus on innovative medical solutions.
BNP Paribas
BNP Paribas is a global financial institution offering a wide range of services, including corporate and institutional banking, and has a significant presence in financing and investment across various sectors, including healthcare.
What's next for Brainsgate?
The recent major strategic investment signals a pivotal growth phase for BrainsGate, likely enabling the company to accelerate its product development pipeline, expand clinical trials, and scale its commercialization efforts. This substantial backing from strategic partners suggests confidence in BrainsGate's technology and its potential to address significant unmet needs in the CNS disease market. The company is poised to leverage this capital to further its mission of providing advanced therapeutic solutions and improving patient outcomes globally.
See full Brainsgate company page
